SNDX: Dominant AML market share, global pivotal trials, and major data readouts expected in Q4 and at ASH
Strong commercial momentum continues with 85%+ market share in key AML segments and robust growth. Two pivotal phase III AML studies are enrolling globally, with additional innovation in IPF, GVHD, and novel oncology programs. Key data readouts are expected in Q4 and at ASH.Based on Syndax Pharmace…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.